| Veröffentlichte Publikationen |
|---|
| Rudi T, Zietemann V, Meissner Y, Zink A, Krause A, Lorenz HM, Kneitz C, Schaefer M, Strangfeld A. Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register. RMD Open. 2024 Apr 4;10(2):e003789. doi: 10.1136/rmdopen-2023-003789. PMID: 38580343; PMCID: PMC11002391. |
Simon TA, Dong L, Suissa S, Michaud K, Pedro S, Hochberg M, Boers M, Askling J, Frisell T, Strangfeld A, Meissner Y, Khaychuk V, Dominique A, Maldonado MA. Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies. Ann Rheum Dis. 2023 Nov 6:ard-2023-224356. doi: 10.1136/ard-2023-224356. Epub ahead of print. PMID: 37932010. |
Meissner Y, Schäfer M, Albrecht K, Kekow J, Zinke S, Tony HP, Strangfeld A. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open 2023;9:e003489. doi: 10.1136/rmdopen-2023-003489. |
Simon TA, Suissa S, Boers M, Hochberg MC, Skovron ML, Askling J, Michaud K, Strangfeld A, Pedro S, Frisell T, Meissner Y, Dominique A, Gomez A. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2023 Jun 30:152240. doi: 10.1016/j.semarthrit.2023.152240. Online ahead of print. |
Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, Lauper K, Mongin D, Iannone F, Pavelka K, Nordström DC, Inanc N, Codreanu C, Hyrich KL, Choquette D, Strangfeld A, Leeb BF, Rotar Z, Rodrigues A, Kristianslund EK, Kvien TK, Elkayam O, Lukina G, Bergstra SA, Finckh A, Courvoisier DS. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries Ann Rheum Dis. 2023 Feb;82(2):175-181. doi: 10.1136/ard-2022-222835. |
Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, Cordtz R, De Cock D, Dreyer L, Elkayam O, Hauge EM, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Kristianslund EK, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Strangfeld A, Verschueren P, Courvoisier DS, Finckh A. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi: 10.1136/annrheumdis-2022-222586. |
Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Schäfer M, Zink A, Strangfeld A. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022 Jan;81(1):41-47. doi: 10.1136/annrheumdis-2021-220651. |
Meissner, Y, Schäfer M, Schneider M, Wilden E, Zinke S, Zink A, Strangfeld A. Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register. RMD Open. 2020 Oct;6(3):e001403. doi: 10.1136/rmdopen-2020-001403. |
Schäfer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A, Strangfeld A. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. RMD Open. 2020 Oct;6(3):e001290; doi: 10.1136/rmdopen-2020-001290. |
Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S, Manger B, Listing J, Strangfeld A, Zink A. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology. 2020 Aug 1;59(8):1916-1926. doi: 10.1093/rheumatology/kez535. |
Baganz L, Listing J, Kekow J, Eisterhues C, Wassenberg S, Zink A, Strangfeld A. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019 Jul 11;doi: 10.1016/j.semarthrit.2019.07.004. [Epub ahead of print]. |
Baganz L, Richter A, Albrecht K, Schneider M, Burmester GR, Zink A, Strangfeld A. Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. Semin Arthritis Rheum. 2019 Jun;48(6):976-982. |
Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C, Listing J, Zink A, Strangfeld A. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Rheumatol Int. 2018 Apr;38(4):579-587. |
Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017 Dec;76(12):2025-2030. |
Meissner Y, Richter A, Manger B, Tony HP, Wilden E, Listing J, Zink A, Strangfeld A. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis. 2017 Sep;76(9):1583-1590. |
Albrecht K, Richter A, Meissner Y, Huscher D, Baganz L, Thiele K, Schneider M, Strangfeld A, Zink A. Wie häufig sind prognostisch ungünstige Faktoren bei Patienten mit rheumatoider Arthritis? Z Rheumatol. 2017 Jun;76(5):434-442. |
Richter A, Meißner Y, Strangfeld A, Zink A. Primary and secondary patient data in contrast: the use of observational studies like RABBIT. Clin Exp Rheumatol. 2016 Sept-Oct;34 Suppl 101(5):79-86. Review. |
Pattloch D, Richter A, Manger B, Dockhorn R, Meier L, Tony H-P, Zink A, Strangfeld A. Das erste Biologikum bei rheumatoider Arthritis: Einflussfaktoren auf die Therapieentscheidung. Z Rheumatol. 2017 Apr;76(3):210-218. |
Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther. 2016 Aug 5;18(1):183. |
Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017 Mar;76(3):504-510. |
Albrecht K, Richter A, Callhoff J, Huscher D, Schett G, Strangfeld A, Zink A. Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases. Arthritis Res Ther. 2016 Jun 23;18:149. |
Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017 Feb;76(2):386-391. |
Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, Zink A, Strangfeld A. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Sep;75(9):1667-73. |
Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab. Ann Rheum Dis. 2015 Feb;74(2):415-21. |
Gerhold K, Richter A, Schneider M, Bergerhausen HJ, Demary W, Liebhaber A, Listing J, Zink A, Strangfeld A. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology (Oxford). 2015 Oct;54(10):1858-66. |
Zink A, Sieper J. Von der Ungewissheit zur Evidenz: Moderne Statistik in der Rheumatologie. Z Rheumatol. 2015 Mar;74(2):104-5. |
Strangfeld A, Richter A. Wie unterstützen Registerdaten die klinische Entscheidungsfindung? Z Rheumatol. 2015 Mar;74(2):119-24. |
Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PL, van de Laar MA, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford). 2015 Jun;54(6):1074-9. |
Strangfeld A, Zink A. Sicherheit unter Biologika – Ergebnisse aus dem deutschen Biologika-Register RABBIT. Dtsch Med Wochenschr. 2014 Sep;139(37):1817-20. |
Krüger K, Strangfeld A, Kneitz C. Sicherheit der Rheumatherapie im Alter. Z Rheumatol. 2014;73(3):244-250. |
Kneitz C, Strangfeld A, Krüger K. Prophylaxe und Behandlung von Infektionen beim älteren Rheumapatienten. Z Rheumatol. 2014;73(3):225-232. |
Richter A, Strangfeld A, Herzer P, Wilden E, Bussmann A, Listing J, Zink A. Sustainability of rituximab therapy in different treatment strategies - results of a 3-year follow-up of the German biologics register RABBIT. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1627-33. |
Zink A, Manger B, Kaufmann J, Eisterhues C, Krause A, Listing J, Strangfeld A. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis. 2014 Sep;73(9):1673-6. |
Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013;52(1):53-61. |
Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914-20. |
Gäwert L, Hierse F, Zink A, Strangfeld A. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology. 2011;50(1):152-160. |
Strangfeld A, Hyrich K, Askling J, Arkema E, Davies R, Listing J, Neovius M, Simard J, Symmons D, Watson K, Zink A. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology. 2011;50(1): 146-151. |
Gäwert L, Hierse F, Zink A, Strangfeld A. Die Bedeutung der Patientensicht bei der Erfassung der Sicherheit neuer Medikamente. Z Rheumatol. 2010;69(9):795–802. |
Zink A, Schneider M. 10 Jahre Behandlung mit TNF-Inhibitoren – Sind wir auf der sicheren Seite? Z Rheumatol. 2010;69(9):772-773. |
Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Seminars in Arthritis and Rheumatism. 2010;40(1):2-14. |
Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5. |
Strangfeld A, Gäwert L, Bussmann A, Gräßler A, Wilden E, Listing J, Zink A. Therapie mit Biologika bei älteren Patienten mit rheumatoider Arthritis – Ergebnisse aus dem deutschen Biologika-Register RABBIT. Treatment with biologics in Older Patients with Rheumatoid Arthritis – Results from the German Biologics Register Rabbit. Akt Rheumatol. 2009;34:291–298. |
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of Herpes Zoster in patients with rheumatoid arthritis treated with anti-TNFalpha agents. JAMA. 2009;301(7):737-744. |
Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A. Comparative effectiveness of TNFalpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856-1862. |
Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A. Does Tumor Necrosis Factor alpha Inhibition Promote or Prevent Heart Failure in Patients With Rheumatoid Arthritis? Arthritis Rheum. 2008;58(3):667-677. |
Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54(11):3399-407. |
Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8:R66. |
Zink A, Listing J, Strangfeld A, Gromnica-Ihle E, Demary W, Schneider M. Dosisanpassung bei Patienten mit rheumatoider Arthritis unter Therapie mit Infliximab in der rheumatologischen Versorgung in Deutschland - Ergebnisse aus dem Biologika-Register RABBIT. Z Rheumatol. 2006;65:441-446. |
Listing J, Strangfeld, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-12. |
|
